Prevention of Recurrent Myocardial Infarction and Sudden Death with Aspirin Therapy

1987 ◽  
Vol 21 (12) ◽  
pp. 961-969 ◽  
Author(s):  
Martha M. Rumore ◽  
George S. Goldstein
Keyword(s):  
Myocardial Infarction ◽  
Clinical Trials ◽  
Clinical Practice ◽  
Sudden Death ◽  
Secondary Prevention ◽  
Aspirin Therapy ◽  
Initial Event ◽  
Current State ◽  
Recurrent Myocardial Infarction ◽  
Acute Mi

In October 1985, the Food and Drug Administration approved a new indication of aspirin for the secondary prevention of recurrent myocardial infarction (MI) and death in patients with MI or unstable angina. Clinical trials have demonstrated the efficacy of this drug, especially when treatment is begun soon after the initial event. The antiplatelet actions of aspirin seem to be the most plausible explanation for its efficacy in reducing mortality and the rate of reinfarction. A single daily 325-mg tablet is effective and produces side-effect incidences of only zero to two percent above those produced by placebo. This article assesses the current state of knowledge regarding the value of aspirin therapy in survivors of acute MI and the implications for clinical practice.

Cell technologies in the treatment of hip osteoarthritis

MedAlliance ◽  
2021 ◽  
Vol 9 (2) ◽  
pp. 29-33
Keyword(s):  
Clinical Trials ◽  
Clinical Practice ◽  
Hip Osteoarthritis ◽  
Current State ◽  
International Registry ◽  
Cell Technologies ◽  
The Subject ◽  
Common Clinical Practice ◽  
Clinical Experiment

SummaryThe article is dedicated to the current state and prospects of cell technologies in the treatment of hip osteoarthritis. The material is based on the analysis of clinical trials on this topic submitted to international registry СlinicalTrials.gov. It has been founded 5 clinical trials relevant to the theme. Only one of these trials was completed with the results pub-lished. It has been stated that the use of cell technologies for the treatment of hip osteoarthritis is still in the stage of a pilot clinical experiment. Thus, it can not yet be the subject of any translation into common clinical practice. At the same time, there is a reason to expect in the upcoming years a serious progress in this direction. This is indicated by the fact that, as of March 1, 2020, the СlinicalTrials.govregistry lists 4 active clinical trials in which the usage of cell technologies in the treatment of hip osteoarthritis is tested. Some of these trials have been already recruiting patients or are ready to begin the recruitment.

Abstract 245: Risk of Readmission With Recurrent Myocardial Infarction After Index Myocardial Infarction

2020 ◽  
Vol 13 (Suppl_1) ◽  
Author(s):  
Raunak Nair ◽  
Michael Johnson ◽  
Kathleen A Kravitz ◽  
Moses Anabila ◽  
Jeevanantham Rajeswaran ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
Patient Outcomes ◽  
Treatment Strategy ◽  
Medical Center ◽  
Parametric Method ◽  
Treatment Strategies ◽  
Recurrent Myocardial Infarction ◽  
Acute Mi ◽  
Increasing Risk ◽  
Considerable Morbidity

Background: Recurrent Myocardial Infarction (MI) after an index MI is a cause for considerable morbidity and mortality. However, the underlying factors that precipitate patients for a recurrent MI remain unclear. We aimed to assess the effect of index MI treatment strategy on the risk of developing a recurrent MI. Methods: We reviewed all cases of MI at a single quaternary care medical center from January 1 st , 2010 to January 1 st , 2017 and identified all cases of recurrent MI within 90 days after index MI. Readmissions were further stratified depending on the treatment strategy undertaken during index MI into medically managed and revascularized patients. The instantaneous risk of readmission following each of these treatment strategies was estimated by the parametric method. Results: We identified 6,626 patients admitted with an index MI, of which 168 patients were readmitted with a recurrent MI within 90 days. Among the index admissions, 4354 (66%) patients underwent revascularization and 2272 (34%) patients underwent medical management. Time-varying instantaneous risk of readmission analysis showed an early peaking risk followed by a late increasing risk in the revascularization group whereas, in the medically managed group, the analysis yielded an early peaking followed by a late almost constant risk of readmission for MI. Conclusion: Patients with acute MI who are medically treated are at a higher risk of developing a recurrent MI than patients who undergo revascularization. Defining the characteristics and underlying factors contributing to these readmissions can be pivotal in improving patient outcomes.

Recurrent myocardial infarction and sudden death after sport

1989 ◽  
Vol 117 (1) ◽  
pp. 188-191 ◽  
Author(s):  
Renzo Ciampricotti ◽  
Mamdouh El Gamal
Keyword(s):  
Myocardial Infarction ◽  
Sudden Death ◽  
Recurrent Myocardial Infarction

scholarly journals Influence of Secondary Prevention and Risk Factors to Recurrent Miocard Infark on Acute Coronary Syndrome Patients in General Hospital Surakarta Indonesia

2019 ◽  
Vol 15 (10) ◽  
pp. 136
Author(s):  
Hidayah Karuniawati Karuniawati ◽  
Vionella Moutika Putri ◽  
Tuqa Haitham
Keyword(s):  
Risk Factors ◽  
Myocardial Infarction ◽  
Secondary Prevention ◽  
Statin Therapy ◽  
Antiplatelet Therapy ◽  
Ace Inhibitor ◽  
Chi Square ◽  
Recurrent Myocardial Infarction ◽  
Myocardial Infraction ◽  
Chi Square Test

<p class="0abstract">The patient who had myocardial infraction has a risk of recurrent myocardial infraction. Secondary prevention including antiplatelet, beta-blocker, statin, ACE inhibitor/ARB aims to prevent recurrent myocardial infarction. This study aimed to find the influence of secondary prevention and risk factors on the occurrence of recurrent myocardial infraction. This research was conducted with quantitative and case-control retrospectively. The subjects were 80 respondents consisting of 40 respondents in the case group and 40 respondents in control group patients. Data were analyzed using bivariate analysis of chi-square test followed by multivariate analysis of logistic regression. Rate of recurrent myocardial infarction (MI) with antiplatelet therapy decreased from 64.3% to 34.2%, with beta-blocker therapy decreased from 57.7% to 35.7%, with statin therapy decreased from 65.9% to 30.5%, with ACE inhibitor/ARB therapy decreased from 65.9% to 30.5%, with a combination of fourth therapy reduced from 57.4% to 34.6%. Chi-square test showed that there was a statistically significant relationship between antiplatelet therapy (p = 0.007), statin therapy (p = 0.002), ACE inhibitor / ARB therapy (p = 0.002), family history (p = 0.011) and adherence (p = 0.007) to recurrent MI. While multivariate analysis of logistic regression showed that the variables influencing the incidence of recurrent myocardial infarction were did not use antiplatelet therapy (P = 0,005; OR= 4.006) and statin therapy (P = 0,029; OR= 3.111). The secondary prevention reduced the incident of recurrent myocardial infarction.</p>

The impact of landmark clinical trials on secondary prevention of acute myocardial infarction (AMI) in Spain. Prevese 98 study

2000 ◽  
Vol 151 (1) ◽  
pp. 107 ◽  
Author(s):  
M. de Oya ◽  
J.L. Lopez-Sendón ◽  
E. de Teresa ◽  
J. Velasco-Rami ◽  
E. Villa ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
Acute Myocardial Infarction ◽  
Clinical Trials ◽  
Secondary Prevention ◽  
The Impact

scholarly journals A phenomenological analysis of the experience of taking medication to prevent a further heart attack

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Hannah Piekarz ◽  
Catherine Langran ◽  
Parastou Donyai
Keyword(s):  
Myocardial Infarction ◽  
Acute Myocardial Infarction ◽  
Clinical Practice ◽  
Secondary Prevention ◽  
Heart Attack ◽  
Interpretative Phenomenological Analysis ◽  
Cardiovascular Events ◽  
Phenomenological Analysis ◽  
Structured Interviews ◽  
Adherence To Medication

AbstractFollowing an acute myocardial infarction, patients are prescribed a regime of cardio-protective medication to prevent recurrent cardiovascular events and mortality. Adherence to medication is poor in this patient group, and not fully understood. Current interventions have made limited improvements but are based upon presumed principles. To describe the phenomenon of medicine-taking for an individual taking medication for secondary prevention for an AMI, Interpretative Phenomenological Analysis was used to analyse transcripts of semi-structured interviews with participants. Themes were generated for each participant, then summarized across participants. Five key themes were produced; the participants needed to compare themselves to others, showed that knowledge of their medicines was important to them, discussed how the future was an unknown entity for them, had assimilated their medicines into their lives, and expressed how an upset to their routine reduced their ability to take medication. Participants described complex factors and personal adaptations to taking their medication. This suggests that a patient-centred approach is appropriate for adherence work, and these themes could inform clinical practice to better support patients in their medicine adherence.

Sign in / Sign up

Export Citation Format

Share Document